Yoshio Ijiri
Overview
Explore the profile of Yoshio Ijiri including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
43
Citations
215
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tanaka S, Noda T, Urashima K, Ijiri Y, Kohda Y, Kato R
J Appl Toxicol
. 2024 Jan;
44(6):846-852.
PMID: 38291012
Trovafloxacin is a quinolone antibiotic drug with broad-spectrum activity, which was withdrawn from a global market relatively soon after approval because of serious liver injury. The characteristics of trovafloxacin-induced liver...
2.
Kato R, Yamada T, Noda T, Tanaka S, Kohda Y, Ijiri Y
Toxicol In Vitro
. 2023 May;
90:105606.
PMID: 37146920
Flutamide is a non-steroidal anti-androgen agent, which is mainly used for the treatment of prostate cancer. Flutamide is known to cause severe adverse events, which includes idiosyncratic liver injury. However,...
3.
Yamada T, Kato R, Ijiri Y, Nishihara M, Neo M
Int J Clin Pharm
. 2023 Jan;
45(2):442-450.
PMID: 36609809
Background: Although acetaminophen is recommended for the treatment of mild-to-moderate cancer pain, acetaminophen-induced hepatic disorders pose an important clinical challenge. Concomitant prescription of immune checkpoint inhibitors (ICIs) may further increase...
4.
Ichihashi A, Inamoto T, Uchimoto T, Nakamura K, Komura K, Yano Y, et al.
In Vivo
. 2023 Jan;
37(1):143-148.
PMID: 36593015
Background/aim: In clinical practice, platinum-based systemic chemotherapy works to shrink pelvic lymph nodes. Intra-arterial (IA) bolus infusion may result in more favorable results than systemic chemotherapy. In the present study,...
5.
Yokoe S, Hayashi T, Nakagawa T, Kato R, Ijiri Y, Yamaguchi T, et al.
Hypertens Res
. 2022 Nov;
46(3):667-678.
PMID: 36376492
Previously, we showed that augmented O-linked N-acetylglucosaminylation (O-GlcNAcylation) mitigates cardiac remodeling in O-GlcNAc transferase-transgenic (Ogt-Tg) mice exposed to acute (2-week) intermittent hypoxia (IH) by suppressing nuclear factor of activated T...
6.
Noda T, Kato R, Ozato Y, Kawai Y, Yamamoto M, Kagawa Y, et al.
Biopharm Drug Dispos
. 2022 May;
43(3):108-116.
PMID: 35508086
Acetaminophen (APAP)-induced liver injury (AILI) is the most common cause of acute liver failure. Although the mechanisms that trigger AILI are well known, it is less understood how to halt...
7.
Noda T, Kato R, Hattori T, Furukawa Y, Ijiri Y, Tanaka K
Life Sci
. 2022 Jan;
294:120351.
PMID: 35092733
Aims: Acetaminophen (APAP) overdose can cause acute liver failure. Although it is well known that APAP-induced liver injury (AILI) is caused by toxic mechanism, recently it is also reported to...
8.
Kato R, Ijiri Y, Hayashi T
Chem Res Toxicol
. 2021 Jun;
34(8):1860-1865.
PMID: 34142814
Amiodarone is a benzofuran derivative used to treat arrhythmias, but its use is limited by adverse reactions. There is evidence that some of the severe adverse reactions such as liver...
9.
Imano H, Kato R, Nomura A, Tamura M, Yamaguchi Y, Ijiri Y, et al.
Biol Pharm Bull
. 2021 Feb;
44(5):669-677.
PMID: 33612567
Pulmonary arterial hypertension (PAH) is a progressive condition that frequently results in right ventricular (RV) remodeling. The objectives of this study are to investigate effects of rivaroxaban on RV remodeling...
10.
Imano H, Kato R, Ijiri Y, Hayashi T
Toxicol In Vitro
. 2020 Dec;
71:105063.
PMID: 33271325
Vascular endothelial growth factor (VEGF) promotes tumor angiogenesis through stimulating the proliferation and survival of endothelial cells. The severe adverse events caused by VEGF inhibitors might include immune-related ones; however,...